Pipeline
Phase 1
Phase 2
Phase 3
Anti-oxLDL Next Generation Antibodies
Preclinical
ORTICUMAB
Psoriasis
with Cardiometabolic Risk
Preclinical
ORTICUMAB
Calcific Aortic Valve Disease
PHASE 2A READY
ORTICUMAB
Rheumatoid Arthritis
PHASE 2A READY
ORTICUMAB
SLE
PHASE 2A READY
Anti-oxLDL Next Generation Antibodies
Post-MI Secondary Prevention
PRECLINICAL
Phase 1
Phase 2
ORTICUMAB
Psoriasis
with Cardiometabolic Risk
ORTICUMAB
Rheumatoid Arthritis
PHASE 2A READY
ORTICUMAB
SLE
PHASE 2A READY
ORTICUMAB
Calcific Aortic Valve Disease
PHASE 2A READY
Phase 3
Our pipeline focuses on indications with substantial residual risk of major cardiovascular events from chronic inflammation
Abcentra’s lead investigational product candidate, orticumab is a first-in-class, fully human monoclonal antibody targeting oxidized low-density lipoprotein (LDL) epitope. We believe that this product has the potential to address several diseases and conditions with substantial risk of major cardiovascular events due to inflammation.
Oxidized LDL is a pro-inflammatory mediator that is implicated in atherosclerotic cardiovascular disease, type 2 diabetes, calcific aortic valve disease and several inflammatory diseases. Oxidized LDL blockade may offer a promising option in the treatment of cardiovascular inflammation, which affects millions of people worldwide.
Orticumab is currently in a phase 2 study in Psoriasis with Elevated Cardiometabolic Risk
Indications
Psoriasis with Cardiometabolic Risk
Psoriasis is a skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term (chronic) disease with no cure. It tends to go through cycles, flaring for a few weeks or months, then subsiding for a while or going into remission.1 Psoriasis is associated with a greater risk of co-morbid cardiovascular (CV) risk factors as well as elevated CV events including myocardial infarction (MI), stroke and cardiovascular death.2 Vascular inflammation and lipoprotein dysfunction are some of the main factors driving accelerated cardiovascular diseases in psoriasis.2
Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a chronic inflammatory disorder that can affect more than just your joints. In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels.3 People with RA have a 50% to 70% higher risk for cardiovascular disease than the general population.4 Chronic inflammation is a key factor that is driving this risk.
Systemic Lupus Erythematosus (SLE)
Systemic lupus erythematosus (SLE) is an autoimmune disease. In this disease, the immune system of the body mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain, and other organs.5 Heart disease is the leading killer in the U.S., but patients with SLE are particularly vulnerable. Young women with lupus are 50 times more likely to die of a heart attack than are young women who don’t have lupus, for example.6 Inflammation is thought to be a key risk factor contributing to this elevated risk.
Calcific Aortic Valve Disease
Calcific aortic valve disease (CAVD) is the most common valve disease worldwide (Nkomo et al., 2006). Epidemiological studies show that 2.8% of adults over 75 years old have some degree of CAVD , and as many as 25% of adults over 65 years old have at least valvular sclerosis (Miller et al., 2011).7 CAVD affects >1 million people in the United States.8
CAVD is a chronic process characterized by progressive fibrotic tissue remodeling and mineralization (Mathieu et al., 2015). Over the years, there is a disease continuum from sclerosis to chronic inflammation and finally leaflet calcification, culminating with severe stenosis. Human pathologic samples have shown that key features in the CAVD development include pathological concentrations of inflammatory cells and lipid species (Otto et al., 1994; O’Brien et al., 1996).7
To date, there is no medical treatment available to prevent or reverse calcium deposition within the valve leaflets. Conventional cardiovascular drugs studied in clinical trials failed to influence the disease progression or reduce adverse outcomes. Surgical options remain the standard-of-care. The mainstay treatment for CAVD is surgical valve replacement and percutaneous implantation of valve prosthesis (Lauten et al., 2013; Lauten et al., 2014; Daubert et al., 2016; Alushi et al., 2019; Wernly et al., 2019).7
Lipoprotein(a) is an independent genetic, causative risk factor for for aortic valve calcification (AVC) and aortic valve stenosis (AVS).8 Lipoprotein(a) is an pro-inflammatory mediator that is closely related structurally to oxidized LDL. Elevated lipoprotein(a) is associated with accelerated CAVD.
Post-Myocardial Infarction (MI) Secondary Prevention
After surviving a MI (or heart attack), risk of having a second heart attack increases. Approximately one in five people who have had a heart attack will be readmitted to the hospital for a second one within five years. Each year, there are about 335,000 recurrent heart attacks in the United States.9 Inflammation is a key factor that drives risk of a recurrent heart attack (see CANTOS Trial 2017).
1 https://www.mayoclinic.org/diseases-conditions/psoriasis/symptoms-causes/syc-20355840
2 https://www.sciencedirect.com/science/article/abs/pii/S1050173819301513?via%3Dihub
3 https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648
5 https://medlineplus.gov/ency/article/000435.htm
6 https://www.lupusresearch.org/heart-disease-common-lupus-new-study-may-explain
7 https://www.frontiersin.org/articles/10.3389/fphar.2020.00685/full
8 https://www.emjreviews.com/cardiology/article/calcific-aortic-valve-stenosis/
